EcoDrugPlus

Dna Topoisomerase Ia

Ensembl ID : ENSOMYG00000023285
Gene Symbol: TOP1A
1 Cross references
201 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOMYG00000027209
Gene Symbol: EML4
1 Cross references
200 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOMYG00000013339
Gene Symbol: EML4
1 Cross references
201 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSOMYG00000062925
Gene Symbol: EPHA3
1 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSOMYG00000029003
Gene Symbol: EPHA3
1 Cross references
206 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOMYG00000043614
Gene Symbol: FYN
1 Cross references
189 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSOMYG00000009496
Gene Symbol: FYNB
1 Cross references
153 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOMYG00000007383
Gene Symbol: HCK
1 Cross references
196 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSOMYG00000011594
Gene Symbol: ITK
1 Cross references
154 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSOMYG00000019899
Gene Symbol: ITK
2 Cross references
195 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSOMYG00000035078
Gene Symbol: IMPDH1B
2 Cross references
256 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSOMYG00000033821
Gene Symbol: IMPDH2
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).